The effect of iron regulatory protein-2 (IRP2) on ferritin expression and neuronal vulnerability to hemoglobin was assessed in primary cortical cell cultures prepared from wild-type and IRP2 knockout mice. Baseline levels of H and L-ferritin subunits were significantly increased in IRP2 knockout neurons and astrocytes. Hemoglobin was toxic to wild-type neurons in mixed neuron-astrocyte cultures, with an LC 50 near 3 µM for a 24 h exposure. Neuronal death was reduced by 85-95% in knockout cultures, and also in cultures containing knockout neurons plated on wild-type astrocytes. Protein carbonylation, reactive oxygen species formation, and heme oxygenase-1 expression after hemoglobin treatment were also attenuated by IRP2 gene deletion. These results suggest that IRP2 binding activity increases the vulnerability of neurons to hemoglobin, possibly by reducing ferritin expression. Therapeutic strategies that target this regulatory mechanism may be beneficial after hemorrhagic CNS injuries.
Introduction
Hemoglobin, the most abundant protein in blood, is present in millimolar concentrations in an intracerebral hematoma. Considerable experimental evidence supports the hypothesis that release of some of this hemoglobin into the extracellular space generates oxidative stress in adjacent tissue (Huang et al., 2002; Koeppen et al., 2004; Qu et al., 2007) . The pro-oxidant effect of hemoglobin in vitro does not appear to be directly due to the hemoglobin molecule per se, but rather to iron (Gutteridge, 1986; Sadrzadeh et al., 1987; Levere et al., 1989; Lamb et al., 1999) , which accumulates in tissue near a hematoma and persists for months (Hua et al., 2006) . Consistent with an iron-mediated effect, iron chelators are protective after injection of either hemoglobin or whole blood into the rodent brain (Huang et al., 2002; Nakamura et al., 2004; Masuda et al., 2007) , and mitigate hemin or hemoglobin neurotoxicity in cell culture models (Regan and Panter, 1993; Goldstein et al., 2003) .
The use of exogenous iron chelators after intracerebral hemorrhage may be limited by their toxicity when administered in the absence of systemic iron overload (Porter and Huehns, 1989; Kushner et al., 2001) . Enhancing the endogenous ability of CNS cells to sequester and detoxify iron may be an alternative or complementary approach. Ferritin, the primary cell iron storage protein, is a 24-mer heteropolymer constructed of H and L subunits that form a hollow protein shell with a capacity for several thousand iron atoms (Harrison and Arosio, 1996; Torti and Torti, 2002; Wagner et al., 2003) . It is induced in astrocytes (Regan et al., 2002) , oligodendrocytes (Qi et al., 1995) and endothelial cells (Balla et al., 1992) by treatment with nontoxic concentrations of heme; preconditioned cells are then protected from toxic doses of hemin and other oxidants. These observations indicate that ferritin is a potent endogenous antioxidant, provided that its expression is increased prior to delivery of an oxidative insult. Although the delayed release of hemoglobin from erythrocytes after intracerebral hemorrhage may provide sufficient time for ferritin induction (Xi et al., 1998) , heme preconditioning may not be feasible in a clinical setting, due to the narrow range between therapeutic and toxic heme concentrations (Balla et al., 1992; Regan et al., 2002) .
Iron regulatory proteins (IRP)-1 and 2 inhibit synthesis of both H and L-ferritin by binding to an iron regulatory element (IRE) in the 5′ regions of their mRNA, thereby preventing translation (Harrison and Arosio, 1996; Torti and Torti, 2002 ). IRP2 appears to predominate in the murine brain and in most tissues, with the exceptions of kidney and brown fat (Meyron-Holtz et al., 2004) . Recent studies have demonstrated that targeting IRP binding activity using pharmacologic or genetic approaches increases ferritin expression in HeLa and C6 glioma cells, and reduces the vulnerability of these cells to oxidative injury (Festa et al., 2000; Wang et al., 2007) . To date, this approach has not been tested on neurons, which are rather inefficient inducers of ferritin after iron or hemoglobin exposure (Bishop and Robinson, 2001; Wu et al., 2003; Koeppen et al., 2004, also unpublished observations) . It therefore remains to be determined if reducing IRP binding activity would increase neuronal ferritin sufficiently to provide a meaningful protective effect. In the present study, the therapeutic potential of Neurobiology of Disease 31 (2008) 242-249 
